Alertix Veterinary Diagnostics AB was founded in 2017. The goal of the company is to commercialize discoveries from Swedish veterinary medical biotech research. In particular concerning a new, powerful method for measuring the presence of the enzyme thymidine kinase 1 (TK1) in serum of animals important in veterinary medicine. TK1 is a biomarker for tumor growth and cell turnover. The substance has been detected in serum of patients even before they show clinical symptoms. This means that the assay can be a valuable tool for early diagnosis of cancer diseases. Unlike previously established methods for detecting TK1 the Alertix method is an immunochemical routine method, which can also successfully detect serum TK1 in patients with solid tumors.
Alertix soon launches a TK1 assay for dogs. Alertix Canine is based on the ELISA standard platform. It is a robust and cost-efficient tool for diagnosing, monitoring and screening tumor diseases. The development of assays for cats and horses is in progress. Our aim is that these assays will be launched no later than 2020. Alertix’ headquarters is located in Kalmar, Sweden. Research is conducted in Uppsala, Sweden.
Alertix shall develop and market in vitro assays and laboratory services for early detection and monitoring of cancer diseases in dogs, cats and horses.
Alertix purpose is to give owners of sports and companion animals more years with their beloved animals.
Alertix shall become a leading actor in the field of diagnostics for early detection, treatment and follow-up of tumor diseases in dogs, cats and horses.